IES86990B2 - Drugs intermediates 1,4-dibromo-2,3-butanediol synthesis method - Google Patents

Drugs intermediates 1,4-dibromo-2,3-butanediol synthesis method Download PDF

Info

Publication number
IES86990B2
IES86990B2 IES20180085A IES20180085A IES86990B2 IE S86990 B2 IES86990 B2 IE S86990B2 IE S20180085 A IES20180085 A IE S20180085A IE S20180085 A IES20180085 A IE S20180085A IE S86990 B2 IES86990 B2 IE S86990B2
Authority
IE
Ireland
Prior art keywords
solution
mol
dibromo
mass fraction
butanediol
Prior art date
Application number
IES20180085A
Inventor
Yan Yida
Original Assignee
Chengdu Dong Dian Ai Er Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Dong Dian Ai Er Tech Co Ltd filed Critical Chengdu Dong Dian Ai Er Tech Co Ltd
Publication of IES20180085A2 publication Critical patent/IES20180085A2/en
Publication of IES86990B2 publication Critical patent/IES86990B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/64Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by simultaneous introduction of -OH groups and halogens

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Drugs intermediates 1,4-dibromo-2,3-butanediol synthesis method, comprises the following steps: the reaction vessel was added 2 mol 1,4-diaminobutanedione, 4-6 mol 2-pyrrolidone, the solution temperature was reduced to 5-7 V, then followed by the addition of 2-3 mol basic bismuth carbonate and 4-6 mol hydrogen bromide solution for 30-60 min, continued to reduce the temperature to 1-3 V, controlled the stirring speed at 170-190 rpm, kept for 40-60 min, standing for 30-50 mm, precipitated the solids, the filtrate was washed with butyric acid methyl ester solution and the nitrile solution, recrystallized from the cyclohexanone solution to precipitate the crystals and the dehydrated with dehydrating agent, obtained the finished product 1,4-dibromo-2,3-butanediol.

Description

FIELD OF THE INVENTION The present invention relates to drugs intermediates l,4-dibromo-2,3-butanediol synthesis method.
GENERAL BACKGROUND I,4-dibromo-2,3-butanediol is mainly used as a drug intermediate. However, most of the existing synthetic methods are using dibromobutene as the reactant, it is complicated and the final yield is not very high. Therefore, it is necessary to propose a new synthetic method for further improving the quality and yield of the product and reducing the byproduct content, it has important economic significance.
SUMMARY The purpose of the present invention is to provide drugs intermediates 1.4- dibromo-2,3-butanediol synthesis method, comprises the following steps: (i) The reaction vessel was added 2 mol 1,4-diaminobutanedione, 4-6 mol 2-pyrrolidone, the solution temperature was reduced to 5-7 °C, then followed by the addition of 2-3 mol basic bismuth carbonate and 4-6 mol hydrogen bromide solution for 30-60 min, continued to reduce the temperature to 1-3 °C, controlled the stirring speed at 170-190 rpm, kept for 40-60 min, standing for 30-50 min, precipitated the solids, the filtrate was washed with butyric acid methyl ester solution and the nitrile solution, recrystallized from the cyclohexanone solution to precipitate the crystals and the dehydrated with dehydrating agent, obtained the finished product 1.4- dibromo-2,3-butanediol; wherein, the mass fraction of the hydrogen bromide solution in step (i) is 15 to 20%, the mass fraction of the butyric acid methyl ester solution in step (i) is 60 to 66% and the mass fraction of the nitrile solution described in step (i) is 75 to 83%, the mass fraction of cyclohexanone solution in step (i) is 90-96%, and the dehydrating agent described in step (i) is any one of anhydrous potassium carbonate and solid sodium hydroxide.
Throughout the reaction process can be the following reaction formula: Br^.
RifoCH2 CH2| I^oh ΟΆ\4 C.,H?NO - (BiOKOvl/2H2O ’ HBr--► H° T IH,C HjC^ ^Br NH2 Advantage of the present invention is that: reducing intermediate links reaction, decreasing the reaction time and improving the reaction yield.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS The following examples with reference to specific embodiments of the present invention are further illustrated: drugs intermediates 1,4-dibromo-2,3-butanediol synthesis method.
Embodiment I The reaction vessel was added 2 mol 1,4-diaminobutanedione, 4 mol 2-pyrrolidone, the solution temperature was reduced to 5 °C, then followed by the addition of 2 mol basic bismuth carbonate and 4 mol hydrogen bromide solution with a 15 mass fraction of 15% for 30min, continued to reduce the temperature to 1 C, controlled the stirring speed at 170 rpm, kept for 40 min, standing for 30 min, precipitated the solids, the filtrate was washed with butyric acid methyl ester solution with a mass fraction of 60% and the nitrile solution with a mass fraction of 75%, recrystallized from the cyclohexanone solution with a mass fraction of 90% to 20 precipitate the crystals and the dehydrated with anhydrous potassium carbonate dehydrating agent, obtained the finished product l,4-dibromo-2,3-butanediol 446.4g, yield of 90%.
Embodiment 2 The reaction vessel was added 2 mol 1,4-diaminobutanedione, 5 mol 2-pyrrolidone, the solution temperature was reduced to 6 “C, then followed by the addition of 2.5 mol basic bismuth carbonate and 5 mol hydrogen bromide solution with a mass fraction of 17% for 40min, continued to reduce the temperature to 2 C, controlled the stirring speed at 180 rpm, kept for 50 min, standing for 40 min, precipitated the solids, the filtrate was washed with butyric acid methyl ester solution with a mass fraction of 63% and the nitrile solution with a mass fraction of 80%, recrystallized from the cyclohexanone solution with a mass fraction of 93% to precipitate the crystals and the dehydrated with solid sodium hydroxide dehydrating agent, obtained the finished product l,4-dibromo-2,3-butanediol 456.32g, yield of 92%.
Embodiment 3 The reaction vessel was added 2 mol 1,4-diaminobutanedione, 6 mol 2-pyrrolidone, the solution temperature was reduced to 7 °C, then followed by the addition of 3 mol basic bismuth carbonate and 6 mol hydrogen bromide solution with a mass fraction of 20% for 60min, continued to reduce the temperature to 3 °C, 15 controlled the stirring speed at 190 rpm, kept for 60 min, standing for 50 min, precipitated the solids, the filtrate was washed with butyric acid methyl ester solution with a mass fraction of 66% and the nitrile solution with a mass fraction of 83%, recrystallized from the cyclohexanone solution with a mass fraction of 96% to precipitate the crystals and the dehydrated with anhydrous potassium carbonate 20 dehydrating agent, obtained the finished product l,4-dibromo-2,3-butanediol 471.2g, yield of 95%.

Claims (3)

1. Drugs intermediates l,4-dibromo-2,3-butanediol synthesis method, comprises the following steps: (i) The reaction vessel was added 2 mol 1,4-diaminobutanedione, 4-6 mol 5 2-pyrrolidone, the solution temperature was reduced to 5-7 °C, then followed by the addition of 2-3 mol basic bismuth carbonate and 4-6 mol hydrogen bromide solution for 30-60 min, continued to reduce the temperature to 1-3 °C, controlled the stirring speed at 170-190 rpm, kept for 40-60 min, standing for 30-50 min, precipitated the solids, the filtrate was washed with butyric acid methyl ester solution and the nitrile 10 solution, recrystallized from the cyclohexanone solution to precipitate the crystals and the dehydrated with dehydrating agent, obtained the finished product 1,4-dibromo-2,3-butanediol; wherein, the mass fraction of the hydrogen bromide solution in step (i) is 15 to 20%, the mass fraction of the butyric acid methyl ester solution in step (i) is 60 to 66% and the mass fraction of the nitrile solution described 15 in step (i) is 75 to 83%.
2. Drugs intermediates l,4-dibromo-2,3-butanediol synthesis method according to claim 1 wherein the mass fraction of cyclohexanone solution in step (i) is 90-96%. 20
3. Drugs intermediates l,4-dibromo-2,3-butanediol synthesis method according to claim 1 wherein the dehydrating agent described in step (i) is any one of anhydrous potassium carbonate and solid sodium hydroxide.
IES20180085A 2017-04-05 2018-03-27 Drugs intermediates 1,4-dibromo-2,3-butanediol synthesis method IES86990B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710216098.8A CN108238847A (en) 2017-04-05 2017-04-05 A kind of synthetic method of bis- bromo- 2,3- butanediols of pharmaceutical intermediate 1,4-

Publications (2)

Publication Number Publication Date
IES20180085A2 IES20180085A2 (en) 2019-04-03
IES86990B2 true IES86990B2 (en) 2019-05-01

Family

ID=58744599

Family Applications (1)

Application Number Title Priority Date Filing Date
IES20180085A IES86990B2 (en) 2017-04-05 2018-03-27 Drugs intermediates 1,4-dibromo-2,3-butanediol synthesis method

Country Status (4)

Country Link
CN (1) CN108238847A (en)
AU (1) AU2018100415A4 (en)
GB (1) GB201705845D0 (en)
IE (1) IES86990B2 (en)

Also Published As

Publication number Publication date
GB201705845D0 (en) 2017-05-24
IES20180085A2 (en) 2019-04-03
AU2018100415A4 (en) 2018-05-10
CN108238847A (en) 2018-07-03

Similar Documents

Publication Publication Date Title
EA036250B1 (en) Method for preparing intermediates for preparing azoxystrobin
MX2023000059A (en) Preparation method for phenylisoxazoline compound.
AU2018100415A4 (en) Drugs intermediates 1,4-dibromo-2,3-butanediol synthesis method
AU2018100389A4 (en) Drugs intermediates m-aminobenzoic acid synthesis method
AU2018100363A4 (en) Drug intermediates aluminium isopropoxide synthesis method
AU2018100387A4 (en) Organic synthesis intermediates m-aminobenzenesulfonic acid synthesis method
AU2018100419A4 (en) Organic intermediates dimethylacetic acid synthesis method
AU2018100364A4 (en) Rivanol medicine intermediates 2-chloro-4-nitrobenzoic acid synthesis method
AU2018100422A4 (en) Drugs intermediates 2-ethylhexanoic acid synthesis method
AU2018100388A4 (en) Medicine intermediates sulfanilic acid synthesis method
AU2018100399A4 (en) Polyester fiber dyeing modifier isophthalic acid synthesis method
CN103709054B (en) Preparation method of DL-leucine
MX2023011603A (en) A process for preparing chlorantraniliprole.
AU2018100424A4 (en) Drugs intermediates 3,4-dimethoxy-6-nitrobenzoic acid synthesis method
AU2018100365A4 (en) Antagonists medicine intermediates o-nitrobenzoic acid synthesis method
IES87001B2 (en) Organic synthesis intermediates N-propenyl urea synthesis method
AU2018100398A4 (en) Blood circulation diagnosis medication o-sulfonamide benzoic acid synthesis method
CN116143674B (en) Synthesis method of high-purity carbocisteine
IES86998B2 (en) Drugs intermediates m-amionbenzoic acid synthesis method
AU2018101117A4 (en) Drug intermediates 3-oxoheptanone ethylene glycol synthesis method
IES86996B2 (en) Organic synthesis intermediates m-aminobenzenesulfonic acid synthesis method
AU2018100367A4 (en) Fluconazole drugs intermediates 2,4-dinitrobenzoic acid synthesis method
AU2018100397A4 (en) Antimalarial medicine intermediates 2,4-dichlorobenzoic acid synthesis method
MX390042B (en) Industrial process for preparing 6-perdesoxy-6-per (2-carboxyethyl) thio-gamma-cyclodextrin sodium salt (sugammadex sodium)
AU2018100393A4 (en) Pyrazinamide drug intermediates p-diazabenzene-2,3-dicarboxylic acid synthesis method